Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

BACKGROUND: Hypoxia is inherent character of most solid malignancies, leading to the failure of chemotherapy, radiotherapy and immunotherapy. Atovaquone, an anti-malaria drug, can alleviate tumor hypoxia by inhibiting mitochondrial complex III activity. The present study exploits atovaquone/albumin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Simeng, Zhou, Xinrui, Zeng, Zekun, Sui, Mengjun, Chen, Lihong, Feng, Chao, Huang, Chen, Yang, Qi, Ji, Meiju, Hou, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487475/
https://www.ncbi.nlm.nih.gov/pubmed/34600560
http://dx.doi.org/10.1186/s12951-021-01034-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487475/
https://www.ncbi.nlm.nih.gov/pubmed/34600560
http://dx.doi.org/10.1186/s12951-021-01034-9

Ejemplares similares